Cantor Fitzgerald restated their overweight rating on shares of Cybin (NYSE:CYBN – Free Report) in a report released on Wednesday, Benzinga reports.
Separately, HC Wainwright reissued a buy rating and issued a $5.00 target price on shares of Cybin in a research note on Wednesday.
Check Out Our Latest Analysis on Cybin
Cybin Stock Performance
Cybin (NYSE:CYBN – Get Free Report) last issued its earnings results on Wednesday, June 26th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Equities analysts expect that Cybin will post -0.09 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new position in shares of Cybin during the 1st quarter worth about $24,041,000. Ikarian Capital LLC acquired a new position in Cybin in the 1st quarter valued at about $5,770,000. Rosalind Advisors Inc. raised its holdings in Cybin by 38.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company’s stock valued at $5,230,000 after acquiring an additional 5,340,000 shares during the period. AWM Investment Company Inc. bought a new stake in shares of Cybin during the first quarter worth approximately $930,000. Finally, PEAK6 Investments LLC acquired a new position in shares of Cybin in the first quarter valued at approximately $95,000. Institutional investors own 17.94% of the company’s stock.
Cybin Company Profile
Cybin Inc is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc is based in Toronto, Canada.
Further Reading
- Five stocks we like better than Cybin
- How to Most Effectively Use the MarketBeat Earnings Screener
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Use Stock Screeners to Find Stocks
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- How to Buy Cheap Stocks Step by Step
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.